

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1-2. (Cancelled)
3. (Currently Amended) A compound according to claim 6, in which
- A or B in each case independently of one another represent hydrogen, tetrazolyl or the group $-\text{N}(\text{CH}_3)_2$, $-\text{NH}(\text{CO})$ -pyrrolidinyl, $-\text{NH}(\text{CO})$ -pentyl, $-\text{NH}(\text{CO})$ -hexyl, $-\text{NH}(\text{CO})$ -hexyl- NH_2 , $-\text{NH}(\text{CO})$ - C_3H_7 , $-\text{NH}(\text{CO})$ - CH_2 -phenyl, $-\text{NH}(\text{CO})$ - CH_2 - NH_2 , $-\text{NH}(\text{CO})$ - C_2H_4 - NH_2 , $-\text{NH}(\text{CO})$ - $\text{CH}(\text{NH}_2)$ - CH_3 , $-\text{NH}(\text{CO})$ - $\text{CH}(\text{NH}_2)$ -hydroxyphenyl, $-\text{NH}(\text{CO})$ - $\text{CH}(\text{NH}_2)$ - CH_2 -phenyl, $-\text{NH}(\text{CO})$ - $\text{CH}(\text{NH}_2)$ - CH_2 -hydroxyphenyl, $-\text{NH}(\text{CO})$ - $\text{CH}(\text{NH}(\text{CO})\text{-CH}_3)$ - CH_2 -phenyl, $-\text{NH}(\text{CO})$ - CH_2 - $\text{NH}(\text{CO})\text{-CH}_3$, $-\text{NH}(\text{CO})$ - $\text{N}(\text{C}_2\text{H}_5)(\text{C}_2\text{H}_4\text{-piperidinyl})$, $-\text{NH}(\text{CO})$ - $\text{N}(\text{CH}_3)(\text{C}_2\text{H}_4\text{-piperidinyl})$, $-\text{NH}(\text{CO})$ - CH_2 - $\text{NH}(\text{CH}_3)$, $-\text{CH}_2\text{-N}(\text{CH}_3)_2$, $-\text{NH}(\text{CO})\text{NH-CH}_2\text{-COOH}$, hydantoinyl, $-\text{CH}_2\text{-COOH}$
- wherein pyrrolidinyl can optionally be substituted with hydroxy or the group $-\text{NH}_2$, $-\text{N}(\text{CH}_3)_2$ or $-\text{NH}(\text{CO})\text{-CH}_3$,
- and wherein hydantoinyl can be substituted with $-\text{CH}_3$, $-\text{CH}_2\text{-COOH}$, or $-(\text{CO})\text{-thiazolidinonyl}$,
- X represents ~~or~~ the group $-\text{NH-}$,
- R^1 represents halogen and
- R^2 represents ~~hydrogen or~~ the group $-\text{NH}(\text{CO})\text{-phenyl}$
- or $\text{C}_2\text{- or } \text{C}_3\text{-alkyl}$ ~~$-\text{C}_2\text{H}_4$, $-\text{C}_3\text{H}_6$~~ both can optionally be substituted in one or more places, the same way or differently, with cyano, hydroxy, phenyl, naphthyl, imidazolyl, thiazolyl, pyridyl, 2-oxazoliny, piperidinyl, $-\text{NH}_2$, $-\text{NH-CH}_2\text{-thienyl}$, $-\text{NH-pyridinyl-NO}_2$, $-\text{NH-thiazolyl}$, $-\text{SO}_2\text{-thienyl}$, $-\text{SO}_2\text{-NH}_2$, $-\text{SO}_2\text{-CH}_3$, $-\text{SO}_2\text{-C}_3\text{H}_7$, pyrrolidinonyl substituted with $-\text{COOH}$, $-\text{NH}(\text{CO})\text{-NH-thienyl}$, $-\text{NH}(\text{CO})\text{-NH-phenyl}$, $-\text{NH}(\text{CO})\text{-NH- C}_2\text{H}_5$, $-\text{NH}(\text{CO})\text{-C}(\text{CH}_3)_3$, $-\text{NH}(\text{CO})\text{-S-C}_2\text{H}_5$, $-\text{NH}(\text{CS})\text{-NH- C}_2\text{H}_5$, $-\text{NH}(\text{CO})\text{-C}_2\text{H}_5$, $-\text{NH}(\text{CO})\text{-thienyl}$, $-(\text{CO})\text{-NH-NH}_2$, $-(\text{CO})\text{-}$

*NC(=O)C(C)(C)C(=O)N, *NC(=O)C1CC1C(=O)N
*NC(=O)C2CCC2C(=O)N, *NC(=O)C1C(F)(F)C2CCC12
*NC(=O)C1CC(=O)NC1=O, *NC(=O)C1CCCC1C(=O)N
*NC(=O)C12CCC(C1)C(=O)N2, *NC(=O)C1CCNC1=O
*NC(=O)C1CCSC1=O or *NC(=O)CCS(=O)(=O)c1ccccc1


4. (Currently Amended) A compound according to claim 6, in which A or B in each case independently of one another represent hydrogen or the group -NH-

(CO)-pyrrolidinyl, -NH-(CO)-piperidinyl, -NH-(CO)-morpholinyl, -NH-(CO)-hexyl-NH₂, -NH-(CO)-CH(NH₂)-hydroxyphenyl, -NH-(CO)-CH(NH₂)-CH₂-hydroxyphenyl, hydantoin optionally substituted with -CH₃,

X represents ~~or~~ the group -NH-,

R¹ represents halogen and

R² represents hydrogen, -C₂H₄-imidazolyl or -C₃H₇ which can optionally be substituted in one or more places, the same way or differently with the group -NH-CH₂-thienyl, -NH-(CO)-C₂H₅, -NH-(CO)-C(CH₃)₃,




or a diastereomer, enantiomer or pharmaceutically acceptable salt thereof.

5. (Previously Presented) A compound, which is
N-[3-[[5-bromo-4-[[3-[[1-(trifluoromethyl)cyclobutyl]carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
N-[3-[[5-bromo-4-[[3-[[1-oxo-3-(phenylsulfonyl)propyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
N-[3-[[4-[[3-[[1-(aminocyclopentyl)carbonyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
N-[3-[[4-[[3-[[1-(aminocyclobutyl)carbonyl]amino]propyl]amino]-5-iodo-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
N¹-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-1,1-cyclopentanedicarboxamide,
(4R)-N-[3-[[5-bromo-2-[[3-(2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide,
(4R)-N-[3-[[5-bromo-2-[[3-(3-methyl-2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide,
3-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-2,4-imidazolidinedione,
3-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-1-methyl-2,4-imidazolidinedione,
N'-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-N-ethyl-N-[2-(1-piperidinyl)ethyl]-urea,
N-[3-[[5-bromo-4-[[3-[(2,2-dimethyl-1-oxopropyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
N-[3-[[2-[[3-[[2S)-2-amino-3-(4-hydroxyphenyl)-1-oxopropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,

N-[3-[[2-[[3-[[1-aminocyclohexyl]carbonyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
 N-[3-[[2-[[3-[[2S)-2-amino-2-phenylacetyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
 N-[3-[[2-[[3-[[2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-5-oxo-2-pyrrolidinecarboxamide,
 N-[3-[[2-[[3-[[2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
 N¹-[3-[[5-bromo-2-[[3-[[2S)-2-pyrrolidinylcarbonyl]amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-1,1-cyclopropanedicarboxamide,
 N-[3-[[5-bromo-2-[[3-(2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
N-(3-((5-bromo-4-((2-((*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-4-morpholinecarboxamide,
N-(3-((5-bromo-4-((2-((*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-1-pyrrolidinecarboxamide,
N-(3-((5-bromo-4-((3-((2-thienylcarbonyl)amino)propyl)amino)-2-pyrimidinyl)amino)phenyl)-1-pyrrolidinecarboxamide,
*N*1-(3-((5-bromo-2-((3-((1-pyrrolidinylcarbonyl)amino)phenyl)amino)-4-pyrimidinyl)-amino)propyl)-1,1-cyclopropanedicarboxamide,
N-(3-((5-bromo-4-((3-((1-oxopropyl)amino)propyl)amino)-2-pyrimidinyl)amino)phenyl)-1-pyrrolidinecarboxamide,
N-(3-((5-iodo-4-((3-((2-thienylcarbonyl)amino)propyl)amino)-2-pyrimidinyl)amino)phenyl)-1-pyrrolidinecarboxamide,
 N-[3-[[5-bromo-4-[[3-[[2S)-5-oxo-2-pyrrolidinyl]carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
 N-[3-[[5-bromo-4-[[3-[[2S)-4-oxo-2-azetidyl]carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
 (4R)-N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide or

N-[3-[[4-[[3-[[[(1-aminocyclobutyl)carbonyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
or a pharmaceutically acceptable salt thereof.

6. (Previously Presented) A compound of formula (I)




in which

A or B in each case independently of one another represent hydrogen or the group --NO_2 , --NH_2 , $\text{--NR}^3\text{R}^4$, $\text{--N(C}_{1-6}\text{-hydroxyalkyl)}_2$, --NH(CO)--R^5 , --NHCOOR^6 , $\text{--NR}^7\text{--(CO)--NR}^8\text{R}^9$, $\text{--NR}^7\text{--(CS)--NR}^8\text{R}^9$, $\text{--CO--NR}^8\text{R}^9$, $\text{--SO}_2\text{--CH}_3$, 4-bromo-1-methyl-1*H*-pyrazolo-3-yl or C_{1-6} -alkyl optionally substituted in one or more places, the same way or differently with cyano, halogen, hydroxy or the group --NH_2 , --NH--(CO)--R^5 , $\text{--SO}_2\text{--NHR}^3$, --COOR^5 , $\text{--CONR}^8\text{R}^9$, --O--(CO)--R^5 , $\text{--O--(CO)--C}_{1-6}\text{-alkyl--R}^5$,

X represents an oxygen atom or the group --NH-- ,

R^1 represents halogen,

R^2 represents C_{1-6} -alkyl optionally substituted in one or more places, the same way or differently, with hydroxy, imidazolyl or the group --NH_2 , $\text{--NH--(CO)O--CH}_2\text{--phenyl}$, --NH--(CO)H , $\text{--NH--(CO)--phenyl}$, $\text{--NH--(CO)--CH}_2\text{--O--phenyl}$, $\text{--NH--(CO)--CH}_2\text{--phenyl}$, $\text{--NH--(CO)--CH(NH}_2\text{)CH}_2\text{--phenyl}$, $\text{--NH--(CO)--CH}_2\text{--CH(CH}_3\text{)--phenyl}$, $\text{--NH--(CO)--CH(NH}_2\text{)--(CH}_2\text{)}_2\text{--COOH}$,



wherein phenyl can optionally be substituted in one or more places, the same or differently with halogen, C₁₋₆-alkyl or $-(CO)-C(CH_2)-C_2H_5$,

R³ or R⁴ in each case independently of one another represent hydrogen or C₁₋₆-alkyl optionally substituted in one or more places, the same way or differently, with hydroxy, phenyl or hydroxyphenyl,
or

R³ and R⁴ together form a C₃₋₆-heterocycloalkylring containing at least one nitrogen atom and optionally can be interrupted by one or more oxygen and/or sulfur atoms and/or can be interrupted by one or more $-(CO)-$ groups in the ring and/or optionally can contain one or more possible double bonds in the ring, wherein the C₃₋₆-heterocycloalkylring can optionally be substituted with C₁₋₆-alkyl, C₁₋₆-alkyl-COOH or C₁₋₆-alkyl-NH₂,

R⁵ represents C₁₋₆-alkyl, C₂₋₆-alkenyl, C₃₋₆-cycloalkyl or phenyl each can optionally be substituted in one or more places, the same way or differently, with halogen, hydroxy, phenyl or with the group $-NH_2$, $-NH(CO)-O-C_{1-6}$ -alkyl, wherein phenyl can optionally be substituted in one or more places, the same way or differently, with halogen, hydroxy or C₁₋₆-alkyl,


R⁶ represents C₁₋₆-alkyl, C₂₋₆-alkenyl or phenyl,

R⁷ represents hydrogen or C₁₋₆-alkyl and

R⁸ or R⁹ in each case independently of one another represent hydrogen, C₁₋₆-alkyl, C₂₋₆-alkenyl, C₃₋₆-cycloalkyl, aryl or phenyl, wherein aryl or phenyl can optionally be substituted in one or more places, the same way or differently, with hydroxy or the group –NO₂ or –N(C₁₋₆-alkyl)₂
or
R⁸ and R⁹ together form a C₃₋₆-heterocycloalkylring containing at least one nitrogen atom and optionally can be interrupted by one or more oxygen and/or sulfur atoms and/or can be interrupted by one or more –(CO)- groups in the ring and/or optionally can contain one or more possible double bonds in the ring, wherein the C₃₋₆-heterocycloalkylring can optionally be substituted with the group –NH₂,
wherein when X represents –NH-, B represents hydrogen and R² represents C₁₋₆-alkyl substituted with –NH₂,
then A represents –NH-(CO)-C₆-cycloalkyl-NH₂,
or a diastereomer, enantiomer or pharmaceutically acceptable salt thereof.

7. (Previously Presented) A compound according to claim 6, in which
A or B in each case independently of one another represent hydrogen or the group –NH-C₂H₄-OH, –NH-CH₂-hydroxyphenyl, –NH-(CO)-pyrrolidinyl, –NH-(CO)-CH(NH₂)-CH₂-phenyl, –NH-(CO)-pentyl-NH₂, –NH-(CO)-hexyl-NH₂, –NH-(CO)-CH₂-NH₂, –NH-(CO)-CH(NH₂)-hydroxyphenyl, –NH-(CO)-CH₂-hydroxyphenyl, –NH-(CO)-CH₂-methylphenyl, –NH-(CO)-C₂H₄-dihydroxyphenyl, –NH-(CO)-CH(OH)-phenyl, –NH-(CO)-CH(NH₂)-CH₂(OH), –NH-(CO)-C(CH₃)₂NH₂, –NH-(CO)-NH(C₂H₅), –CH₂OH, –(CO)-NH-cyclopropyl, –(CO)-NH-CH(CH₃)₂,
wherein pyrrolidinyl can optionally be substituted with hydroxy or the group –NH₂,
X represents an oxygen atom or the group –NH-,
R¹ represents halogen and
R² represents –C₂H₅ optionally substituted in one or more places, the same way or differently, with hydroxy, imidazolyl
or represents –C₃H₇ or –C₄H₈ optionally substituted in one or more places, the

same way or differently with the group $-\text{NH}_2$, $-\text{NH}(\text{CO})\text{CH}(\text{NH}_2)\text{C}_2\text{H}_4\text{COOH}$, $-\text{NH}(\text{CO})\text{-phenyl}$, $-\text{NH}(\text{CO})\text{-CH}_2\text{-phenyl}$, $-\text{NH}(\text{CO})\text{-CH}_2\text{-CH}(\text{CH}_3)\text{-phenyl}$, $-\text{NH}(\text{CO})\text{-CH}_2\text{-O-phenyl}$, $-\text{NH}(\text{CO})\text{O-CH}_2\text{-phenyl}$, $-\text{NH}(\text{CO})\text{-CH}(\text{NH}_2)\text{CH}_2\text{-phenyl}$,



wherein phenyl can optionally be substituted in one or more places, the same or differently, with halogen, $-\text{CH}_3$ or $-(\text{CO})\text{-C}(\text{CH}_2)(\text{C}_2\text{H}_5)$, or a diastereomer, enantiomer or pharmaceutically acceptable salt thereof.

8. (Previously Presented) A compound, which is
 N-[3-[[2-[[3-[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
 1-[3-[[2-[[3-[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2-oxo-3-pyrrolidinecarboxylic acid,
 N-[3-[[5-bromo-4-[[3-[(5-oxo-2-pyrrolidinyl)carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
 Pyrrolidine-1-carboxylic acid [3-(5-bromo-4-{3-[2-(2,4-dichloro-phenyl)-acetyl-amino]-propyl-amino}-pyrimidin-2-yl-amino)-phenyl]-amide,
 Pyrrolidine-1-carboxylic acid [3-(5-bromo-4-{3-[2-(4-bromo-phenyl)-acetyl-amino]-

propylamino}-pyrimidin-2-ylamino)-phenyl]-amide,
 Pyrrolidine-1-carboxylic acid (3-{5-bromo-4-[3-(2-p-tolyl-acetylamino)-propylamino]-pyrimidin-2-ylamino}-phenyl)-amide,
 Pyrrolidine-1-carboxylic acid [3-(5-bromo-4-{3-[2-(2,4-difluoro-phenyl)-acetylamino]-propylamino}-pyrimidin-2-ylamino)-phenyl]-amide,
 Pyrrolidine-1-carboxylic acid {3-[5-bromo-4-(3-{2-[2,3-dichloro-4-(2-methylene-butyryl)-phenoxy]-acetylamino}-propylamino)-pyrimidin-2-ylamino]-phenyl}-amide,
 Pyrrolidine-1-carboxylic acid [3-(5-bromo-4-{3-[3-(2,3-dichloro-phenyl)-butyrylamino]-propylamino}-pyrimidin-2-ylamino)-phenyl]-amide,
 Pyrrolidine-1-carboxylic acid (3-{5-bromo-4-[3-(3-bromo-benzoylamino)-propylamino]-pyrimidin-2-ylamino}-phenyl)-amide,
N-(3-((4-((4-aminobutyl)amino)-5-bromo-2-pyrimidinyl)amino)phenyl)-1-pyrrolidinecarboxamide,
N-[3-[[2-[[3-[(2*R*)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
N-[3-[[2-[(2*S*)-2-Amino-1-oxo-3-phenylpropyl]amino]-5-[[5-bromo-4-(prop-2-ynyloxy)pyrimidin-2-yl]amino]phenyl]pyrrolidine-1-carboxamide,
N-[3-[[2-[(2*R*)-2-Amino-1-oxo-3-phenylpropyl]amino]-5-[[5-bromo-4-(prop-2-ynyloxy)pyrimidin-2-yl]amino]phenyl]pyrrolidine-1-carboxamide,
 (*αR*)-*α*-Amino-*N*-[3-[[5-bromo-4-(prop-2-ynyloxy)pyrimidin-2-yl]amino]-5-(hydroxymethyl)phenyl]benzenepropanamide,
 2-[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-5-hydroxymethyl-phenylamino]-ethanol,
 (2*R*)-Amino-*N*-[3-hydroxymethyl-5-(4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-phenyl-propionamide,
 3-((2*R*)-Amino-3-phenyl-propionylamino)-5-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-*N*-cyclopropyl-benzamide,
 3-((2*R*)-Amino-3-phenyl-propionylamino)-5-(5-bromo-4-prop-2-ynyloxy-pyrimidin-2-ylamino)-*N*-isopropyl-benzamide,
 Phenylmethyl [3-[[2-[[3-[(ethylamino)carbonyl]amino]phenyl]amino]-5-

(hydroxymethyl)pyrimidine-4-yl]amino]propyl]carbamate,

Pyrrolidine-1-carboxylic acid (3-{4-[3-((2R)-amino-3-phenyl-propionylamino)-propylamino]-5-bromo-pyrimidine-2-ylamino}-phenyl)-amide,

Pyrrolidine-1-carboxylic acid (3-{4-[3-((2S)-amino-3-phenyl-propionylamino)-propylamino]-5-bromo-pyrimidine-2-ylamino}-phenyl)-amide,

2-[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenylamino]-ethanol,

1-Amino-cyclopentancarbonylic acid[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-amide,

1-Amino-cyclohexancarbonylic acid-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-amide,

(2S)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-phenyl-propionamide,

(2R)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-phenyl-propionamide,

2-[[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenylamino]-methyl]-phenol,

(2R)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-(4-hydroxy-phenyl)-propionamide,

N-[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-(3,4-dihydroxy-phenyl)-propionamide,

N-[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-2-hydroxy-(2S)-phenyl-acetamide,

N-[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-2-hydroxy-(2R)-phenyl-acetamide,

(2S)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-hydroxy-propionamide,

(2R)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidin-2-ylamino)-phenyl]-3-hydroxy-propionamide,

2-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-2-methyl-propionamide,

(2S)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-(4-hydroxy-


phenyl)-propionamide,

(2S)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-p-tolyl-propionamide or

(2R)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-p-tolyl-propionamide,

or a pharmaceutically acceptable salt thereof.

9. (Previously Presented) A compound according to claim 6, in which
A or B in each case independently of one another represent hydrogen or the group -SO₂-CH₃, -NO₂, -NH₂, -CF₃, -CH₂-NH-(CO)-NH₂, -CH₂-pyrrolidinyl, -NH-(CO)-CH₃, -NH-(CO)-hexyl-NH₂, -NH-(CO)-phenyl, -NH-(CO)-pyrrolidinyl, -NH-(CO)-CH(NH₂)-CH₂-phenyl, NH-(CO)-OCH₃, -NH-(CO)-OCH(CH₃)₂, -NH-(CO)-OC₂H₄-morpholino, -NH-(CO)-NH-cyclopropyl, -NH-(CO)-morpholino, -NH-(CO)-NH-C₂H₄-morpholino, -NH-(CO)-NH-hydroxycycloalkyl, hydantoinyl, wherein pyrrolidinyl can optionally be substituted with hydroxy or the group -NH₂ and wherein hydantoinyl can optionally be substituted with the group -CH₃ or -(CO)-thiazolidinonyl,
X represents the group -NH-,
R¹ represents halogen and
R² represents -CH₂-dihydroxyphenyl, -C₂H₄-imidazolyl, or -C₃H₇ optionally substituted in one or more places, the same way or differently, with



or a diastereomer, enantiomer or pharmaceutically acceptable salt thereof.

10. (Previously Presented) A compound, which is
4-((4-((2-(1H-imidazol-4-yl)ethyl)amino)-5-iodo-2-pyrimidinyl)amino)-benzenesulfonamide,
N-((3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)methyl)-
urea,
1-((3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)methyl)-3-
pyrrolidinol,
(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-carbamic acid
methyl ester,
N2-(3-aminophenyl)-5-bromo-N4-(2-(1H-imidazol-4-yl)ethyl)-2,4-pyrimidinediamine,
N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-N'-
cyclopropyl-urea,
N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-4-
morpholinecarboxamide,
(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-carbamic acid
1-methylethyl ester,
N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-
methanesulfonamide,
N2-(3-amino-5-(trifluoromethyl)phenyl)-5-bromo-N4-(2-(1H-imidazol-4-yl)ethyl)-2,4-
pyrimidinediamine,
N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-N'-(2-(4-
morpholinyl)ethyl)-urea,
N2-(3-amino-5-chlorophenyl)-5-bromo-N4-(2-(1H-imidazol-4-yl)ethyl)-2,4-pyrimidinediamine,
(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-carbamic acid
2-(4-morpholinyl)ethyl ester,
N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-N'-(4-
hydroxycyclohexyl)-urea,
N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-acetamide,
N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-benzamide,

(4R)-N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide,
 3-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-2,4-imidazolidinedione,
 3-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-1-methyl-2,4-imidazolidinedione,
 1-[3-[[2-[[3-[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2-oxo-3-pyrrolidinecarboxylic acid,
 1-[3-[[2-[[3-[(1-aminocyclohexyl)carbonyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2-oxo-3-pyrrolidinecarboxylic acid,
 N-[3-[[2-[[3-[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-5-oxo-2-pyrrolidinecarboxamide,
 N-[3-[[2-[[3-[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-chloro-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
 3-[3-[[5-bromo-4-[(3,4-dihydroxyphenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]-2,4-imidazolidinedione,
 3-[3-[[5-bromo-4-[(3,4-dihydroxyphenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]-1-methyl-2,4-imidazolidinedione,
 (4R)-N-[3-[[5-bromo-2-[[3-(2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide,
 N-[3-[[5-bromo-2-[[3-(2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-5-oxo-2-pyrrolidinecarboxamide,
 N-[3-[[5-bromo-2-[[3-(2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
 3-[3-[[5-bromo-4-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]-2-pyrimidinyl]amino]phenyl]-2,4-imidazolidinedione,
 (4R)-N-[3-[[5-bromo-2-[[3-(3-methyl-2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide or
 (4R)-N-[3-[[5-bromo-2-[[3-[2,5-dioxo-3-[(4R)-2-oxo-4-thiazolidinyl]carbonyl]-1-imidazolidinyl]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide,

or a pharmaceutically acceptable salt thereof.

11. (Cancelled)

12. (Previously Presented) A pharmaceutical composition comprising at least one compound according to claim 6 and a pharmaceutically acceptable carrier, diluent or excipient.

13-16. (Cancelled)

17. (Currently Amended) A method of treating Kaposi sarcoma, Hodgkin's disease or leukemia comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 12.

18. (Cancelled)

19. (Previously Presented) A method according to claim 17, wherein the patient treated is a mammal.

20. (Previously Presented) A method of claim 19, wherein the mammal is a human.

21-25. (Cancelled)

26. (Currently Amended) A pharmaceutical composition comprising at least one compound according to claim 3 ~~44~~ and a pharmaceutically acceptable carrier, diluent or excipient.

27. (Previously Presented) A method of treating Kaposi sarcoma, Hodgkin's disease or leukemia comprising administering to a patient in need thereof an effective amount of

a pharmaceutical composition according to claim 26.

28. (Cancelled)

29. (Previously Presented) A method of treating rheumatoid arthritis comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 12.

30-31. (Cancelled)

32. (Previously Presented) A compound according to claim 6, wherein X represents an oxygen atom.


33. (Previously Presented) A compound according to claim 6, wherein X represents the group -NH-.

34. (Previously Presented) A compound according to claim 6, wherein A or B in each case independently of one another represent hydrogen or the group -NO₂, -NH₂, -NR³R⁴, -N(C₁₋₆-hydroxyalkyl)₂, -NH(CO)-R⁵, -NHCOOR⁶, -NR⁷-(CO)-NR⁸R⁹, -NR⁷-(CS)-NR⁸R⁹, -CO-NR⁸R⁹, -SO₂-CH₃, 4-bromo-1-methyl-1*H*-pyrazolo-3-yl or C₁₋₆-alkyl optionally substituted in one or more places, the same way or differently with cyano, hydroxy or the group -NH₂, -NH-(CO)-R⁵, -SO₂-NHR³, -COOR⁵, -CONR⁸R⁹, -O-(CO)-R⁵, -O-(CO)-C₁₋₆-alkyl-R⁵.

35. (Cancelled)

36. (Previously Presented) A compound according to claim 6, wherein R² represents C₁₋₆-alkyl optionally substituted in one or more places, the same way or differently, with hydroxy, imidazolyl or the group -NH-(CO)O-CH₂-phenyl, -NH-(CO)H, -NH-(CO)-phenyl, -NH-(CO)-CH₂-O-phenyl, -NH-(CO)-CH₂-phenyl, -


NH-(CO)-CH(NH₂)CH₂-phenyl, -NH-(CO)-CH₂-CH(CH₃)-phenyl, -NH-(CO)-CH(NH₂)-(CH₂)₂-COOH,



wherein phenyl can optionally be substituted in one or more places, the same or differently with halogen, C₁₋₆-alkyl or -(CO)-C(CH₂)-C₂H₅.

37-38. (Cancelled)

39. (Previously Presented) A compound according to claim 6, wherein R² represents a straight chain or branched chain C₁₋₆-alkyl substituted in one or more places, the same way or differently, with hydroxy, imidazolyl or the group -NH₂, -NH-(CO)O-CH₂-phenyl, -NH-(CO)H, -NH-(CO)-phenyl, -NH-(CO)-CH₂-O-phenyl, -NH-(CO)-CH₂-phenyl, -NH-(CO)-CH(NH₂)CH₂-phenyl, -NH-(CO)-CH₂-CH(CH₃)-phenyl, -NH-(CO)-CH(NH₂)-(CH₂)₂-COOH,



wherein phenyl can optionally be substituted in one or more places, the same or differently with halogen, C₁₋₆-alkyl or $-(CO)-C(CH_2)-C_2H_5$.

40. (Previously Presented) A pharmaceutical composition comprising at least one compound according to claim 39 and a pharmaceutically acceptable carrier, diluent or excipient.

41. (Currently Amended) A method of treating Kaposi sarcoma, Hodgkin's disease or leukemia comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim ~~40~~ 42.